Conclusion
asthma
ASTHMA
While no single patient characteristic was a strong predictor for benefit of mepolizumab in severe asthma, the combination of multiple characteristics could reasonably predict treatment response of mepolizumab in severe asthma, in particular improvement in asthma symptom control. This indicates that individualized, covariate-informed treatment rules have the potential to improve the efficiency of biologic therapies and their value proposition. Such gain in efficiency should be pursued in tandem with other efforts in improving the efficiency of biologic therapy, such as ensuring the treatment is given to truly eligible patients, improving adherence to inhaled therapies and inhaler technique before prescribing biologics, and continuing negotiations on the price of biologics. These findings call for future research on developing precision medicine tools for treatment selection and validating them in representative samples.